Philippe Lebel

Other techniques for monitoring cannabinoids, such as GC–MS and LC–MS, are limited to screening known species and are therefore always one step behind the designer drug market-where new, previously unknown variations of analogs of cannabinoids are constantly being synthesized. The method presented here addresses this problem by providing accurate masses for all detected species, thus allowing postanalysis identification of initially untargeted compounds.